Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Tofacitinib Industry?

In recent times, the tofacitinib market has experienced swift expansion. Its growth is forecasted to escalate from $3.08 billion in 2024 to $3.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.9%. The increase in the previous period can be traced back to successful clinical efficacy and trials, regulatory authorizations, the growing occurrence of targeted conditions, physicians’ prescribing behaviors, and patient acceptance.

The market size of tofacitinib is set to witness a substantial increase in the upcoming years. It is projected to expand to “$5.67 billion in 2029 with a compound annual growth rate (CAGR) of 13.5%.” The expansion during the anticipated period is due to the increase in indications, market access strategies, the influence of competition, real-world results, and a patient-oriented healthcare approach. The key trends within the prediction period consist of emphasis on treatment for juvenile rheumatoid arthritis, the use of tofacitinib for skin conditions, tactical collaborations and associations, the use of real-world data in treatment protocols, and stress on tailored medical methods.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10779&type=smp

#Which Factors Are Currently Driving The Growth Of The Tofacitinib Market?

The increase in the incidence of rheumatoid arthritis is anticipated to drive the expansion of the tofacitinib market. An autoimmune inflammatory condition, rheumatoid arthritis primarily impacts hands, feet, other joints, and internal organs. Tofacitinib treatments work by inhibiting the activity of Janus kinase enzymes, thus preventing them from contributing to the inflammation that leads to rheumatoid arthritis symptoms. For example, the National Arthritis Data Workgroup reported in February 2022 that over 52.5 million adult Americans, equating to more than 22% of the population, have been diagnosed with arthritis or another rheumatic condition. By 2030, the number of adults aged 18 and older diagnosed with arthritis is expected to reach 67 million. As a result, the increasing incidence of rheumatoid arthritis is fueling the growth of the tofacitinib market.

The tofacitinib market covered in this report is segmented –

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant

2) By Strength: 5mg, 10mg, 11mg, 22mg

3) By Route Of Administration: Oral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications

Subsegments:

1) By Antirheumatic: Conventional Synthetic Antirheumatics, Targeted Synthetic Antirheumatics

2) By Janus Kinase Inhibitor: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors

3) By Immunosuppressant: Corticosteroids, Non-Steroidal Immunosuppressants

What Notable Trends Are Shaping The Direction Of The Tofacitinib Market?

Predominant entities in the tofacitinib market are focusing on the formulation of novel ointments such as the tofacitinib ointment in order to boost targeted dissemination and improve the results of treatment for patients suffering from inflammatory skin conditions. The tofacitinib ointment is a topical JAK inhibitor and serves as an excellent treatment for mild to moderate atopic dermatitis, thus presenting a new alternative in the tofacitinib market by providing a steroid free solution for patients with ongoing treatment needs. A case in point, Intas Pharmaceuticals Ltd., a pharmaceutical company based in India, in June 2023, introduced tofatas, a tofacitinib ointment with a 2% w/w concentration that has been approved by DCGI for the treatment of mild to moderate atopic dermatitis (AD) in adults. This introduction marks the first approved topical JAK inhibitor in India, closing a 15-year pause in the innovation of therapies for this condition. Pursuing a steroid free approach, tofatas covers a significant treatment shortfall, potentially ameliorating patient lifestyle quality and expanding therapeutic applications of tofacitinib in the field of dermatology.

Who Are The Main Participants Shaping The Tofacitinib Market Landscape?

Major companies operating in the tofacitinib market include Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd, Aprazer Healthcare Pvt Ltd, Apino Pharma Co Ltd, Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Which Region Currently Holds The Largest Share In The Tofacitinib Market?

North America was the largest region in the tofacitinib market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10779&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model